{
    "nctId": "NCT06470672",
    "briefTitle": "Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer",
    "officialTitle": "A Phase 2 Study of SHR-A1921 Combined Adebrelimab in Endocrine Therapy-failed HR-positive, HER2-negative Advanced Breast Cancer",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 32,
    "primaryOutcomeMeasure": "ORR by investigator",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years to 75 years old, female patients with breast cancer;\n* ECOG PS Score: 0\\~1;\n* Histologically or cytologically confirmed HR-positive, HER2-negative advanced or metastatic breast cancer;\n* PD-L1 positive;\n* Disease progression after at least prior 2 lines of endocrine therapy, and unable to benefit from further endocrine therapy determined by investigator, of which at least one line of CDK4/6 inhibitor-based treatment; if recurrence or metastasis within 2 years after completion of adjuvant endocrine therapy, marked as first-line treatment;\n* Prior at least 1 line of systemic chemotherapy in recurrent or metastatic setting;\n* Based on RECIST v1.1, at least one measurable lesion;\n* Patients must have a life expectancy \u2265 3 months;\n* Adequate organ function and marrow function (no corrective treatment within 14 days before first dose);\n* Women of childbearing potential (WOCBP) should agree to use an effective method of contraception and no lactation from the initiation of screening to 7 months after the last dose of study therapy; WOCBP should have a negative serum pregnancy result within 7 days before the first dose of study therapy;\n* Willing and able to provide written informed consent and comply with the requirements and restrictions in the protocol.\n\nExclusion Criteria:\n\n* Has leptomeningeal metastasis confirmed by MRI or lumbar puncture;\n* Has CNS metastasis confirmed by radiology, except following conditions: \u2460asymptomatic brain metastasis that is not required to radiotherapy or surgery immediately; \u2461prior local therapy (e.g. radiotherapy or surgery) for brain or dural metastasis, of which stable disease lasting at least 4 weeks confirmed by radiography, and symptomatic therapy (e.g. hormone, mannitol, bevacizumab) has been stopped beyond 2 weeks with no clinical symptom;\n* Prior anti-TROP-2 treatment;\n* Has received or been receiving PD-(L)1 inhibitors and/or ADC containing a topoisomerase inhibitor-like payload;\n* Existence of third space fluid (e.g. massive ascites, pleural effusion, pericardial effusion) that is not well controlled by effective methods, e.g. drainage;\n* Has received antitumor surgery, radiotherapy, chemotherapy, targeted therapy or immunological therapy within 4 weeks before first dose of study therapy; has received antitumor endocrine therapy within one week before first dose of study therapy;\n* Use of other antitumor systemic treatment during the study;\n* Has active autoimmune disease or a history of autoimmune disease;\n* Known history of immunodeficiency, including HIV-positive, other acquired or innate immunodeficient disease, or known history of organ transplantation;\n* Has active hepatitis B (HBsAg-positive and HBV DNA\u2265500 IU/mL), hepatitis C (positive for HCV antibody and HCV RNA above ULN) and hepatic cirrhosis;\n* Has an active infection requiring antibiotics, antiviral or antifungal treatment, or pyrexia \\>38.5\u2103 of unknown origin during the screening period before first dose of study therapy (patients with pyrexia due to cancer could be enrolled determined by investigator);\n* Receiving immunosuppressive medication, or systemic corticosteroid therapy for the purpose of immunosuppression (prednisone at \\>10mg/d or equivalent dose of other corticosteroids), and continuous use within 2 weeks before the first dose of study therapy;\n* Other malignancy within prior 5 years unless curatively treated with no evidence of disease for at least recent 3 years, except: curatively treated in situ cancer of the cervix, skin basal cell carcinoma or skin squamous cell carcinoma;\n* Hypersensitivity to study therapy or any of its excipients;\n* Has known clinically significant lung disease, including but not limited to: interstitial lung disease, pneumonitis, pulmonary fibrosis;\n* Known history of uncontrolled cardiovascular clinical symptom or disease that is not well controlled;\n* Has received a live vaccine within 4 weeks before first dose of study therapy, or potential to receive a live vaccine during the trial treatment;\n* Other conditions that might influence the study and analysis of results in the opinion of the investigator.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}